S. Korean firm gets order for cloned dog

Here's a new business model for biotechnology: Pet cloning. South Korea's RNL Bio says it has its first $50,000 order to clone a dog from the biologic material remaining from a California woman's pet bull terrier. If more orders arrive, RNL says that it will hike its price to a post-launch $150,000. The company expects most of its cloned animals will be used in biomedical work and security. The company says they'll need to first make sure that the biologic material they're working with is viable for cloning purposes. If it is, they'll get started in April.

- check out the article from The Wall Street Journal

Related Articles:
S. Korean team to attempt first monkey clone. Report
Mature stem cells prove effective in cloning. Report
U.S. scientists renew stem cell cloning efforts. Report

Suggested Articles

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.

The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi an IL-2 drug it thinks can become a foundation of future cancer combinations.